Uefa fine Tottenham Hotspur and give them a suspended ban from selling away tickets after three supporters made Nazi salutes towards Eintracht Frankfurt fans.
Uefa fine Tottenham Hotspur and give them a suspended ban from selling away tickets after three supporters made Nazi salutes towards Eintracht Frankfurt fans.
Earnings Call Insights: AAON, Inc. (AAON) Q4 2025 Management View Matthew Tobolski, President and CEO, described 2025 as "a year marked by several notable achievements delivered alongside transformational investments that are building a more resilient and scalable business." He highlighted robust bookings and revenue momentum, particularly in the data center market, where BASX branded sales increa...
Earnings Call Insights: AAON, Inc. (AAON) Q4 2025 Management View Matthew Tobolski, President and CEO, described 2025 as "a year marked by several notable achievements delivered alongside transformational investments that are building a more resilient and scalable business." He highlighted robust bookings and revenue momentum, particularly in the data center market, where BASX branded sales increased 143% to $548 million, and backlog grew 141% to $1.3 billion. Tobolski emphasized the book-to-bill of 2.4 for the BASX brand for the year, and noted that "AAON branded sales and bookings remained resilient in 2025 and particularly in light of a 16% decline in overall industry volumes." He discussed strategic investments in manufacturing capacity, supply chain management, product development, and IT systems, as well as the introduction of rooftop units with cold climate heat pumps capable of reliable heating at negative 20 degrees Fahrenheit. Tobolski stated, "BASX branded bookings again reached record levels, driving backlog to $1.3 billion up 45% sequentially and 141% year-over-year. AAON branded bookings were also strong and increased 20% year-over-year with backlog up 24% sequentially and 61% from the prior year period." Rebecca Thompson, Interim Principal Accounting Officer, CFO & Treasurer, reported, "Net sales in the fourth quarter increased 42.5% year-over-year to $424.2 million. The increase was driven primarily by 138.8% growth in BASX branded sales." She noted that AAON branded sales grew 9.5% in the fourth quarter, and gross margin was 25.9%, down from 26.1% in the prior year period. Thompson stated that fourth quarter non-GAAP adjusted EBITDA margin was 15.2%, with diluted EPS at $0.39, up 30% from the fourth quarter of 2024. Outlook Tobolski projected, "For the year, we anticipate sales growth of 18% to 20% and a gross margin of 29% to 31%, with margin progression expected to be uneven by quarter as capacity ramps and product mix normalizes." He also stated,...
Earnings Call Insights: Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Management View CEO John Shannon stated the company "reached a defining milestone, financial self-sustainability," highlighting that Xeris is now able to self-fund strategy, pipeline, and future growth. He reported "fourth quarter total revenue grew 43% year-over-year to nearly $86 million," with full-year revenue increasing 44%...
Earnings Call Insights: Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Management View CEO John Shannon stated the company "reached a defining milestone, financial self-sustainability," highlighting that Xeris is now able to self-fund strategy, pipeline, and future growth. He reported "fourth quarter total revenue grew 43% year-over-year to nearly $86 million," with full-year revenue increasing 44% to $292 million. Xeris delivered nearly $60 million in adjusted EBITDA and achieved net income for the first time on a full-year basis. Shannon called Recorlev "the primary growth engine" and cited a doubling of the patient base to approximately 700 by year-end. The commercial team for Recorlev was nearly doubled in January to accelerate adoption, and the company filed a patent infringement lawsuit to defend Recorlev's intellectual property, noting "4 Orange Book-listed patents that run until March 2040 and orphan drug exclusivity...through the end of 2028." Gvoke posted 14% full-year revenue growth, and Keveyis continued to outperform with increased patient numbers. Shannon shared ongoing confidence in XP-8121, with Phase III initiation targeted for the second half of 2026 and peak sales potential of $1 billion to $3 billion. CFO Steven Pieper stated, "Total revenue for the fourth quarter was $85.8 million, representing 43% growth year-over-year." He emphasized "improved balance sheet" and noted "adjusted EBITDA for the fourth quarter was $25.1 million...for the full year, adjusted EBITDA was $59.4 million." Outlook Shannon provided 2026 guidance with "total revenue between $375 million and $390 million, representing more than 30% growth at the midpoint compared to 2025." Pieper added, "We expect R&D to increase by approximately $25 million" due to Phase III XP-8121 initiation and "plan to increase SG&A by approximately $45 million in 2026 primarily due to the expansion we recently completed." The company plans to remain adjusted EBITDA positive in 2026, with adjusted EBI...
Torsten Asmus/iStock via Getty Images The iShares International Treasury Bond ETF ( IGOV ) has quite a lot of exposure to Japanese government bonds and, other than that, various European bonds—the point of this ETF would be to get government exposure but without any US Treasuries, ETFs for which are super common. For Japanese bonds, our concern is that there continue to be risks to the JPY, as rat...
Torsten Asmus/iStock via Getty Images The iShares International Treasury Bond ETF ( IGOV ) has quite a lot of exposure to Japanese government bonds and, other than that, various European bonds—the point of this ETF would be to get government exposure but without any US Treasuries, ETFs for which are super common. For Japanese bonds, our concern is that there continue to be risks to the JPY, as rate hikes can't help the currency in the current political matrix, but rate cuts also seem unlikely for lifting duration bets. Moreover, yield to maturity may rise just on the bonds becoming more unattractive from here, especially painful at higher durations. For European bonds, we note that there is upside to debt-to-GDP ratios, which is deleterious to prices, and the cuts in Europe have already taken place post-inflation battle, so we don't see much additional upside on cuts. We aren't particularly bearish except on maybe Japanese bonds, and they are only one part of the portfolio, but there's no reason to hop onto IGOV either except perhaps the additional recent angle provided by the strikes now initiated on Iran by the US and its allies . The tensions will likely strengthen the dollar, in part due to speculation on oil prices, which are dollar-denominated, but also because of the implications on the US maritime order, which was seen as one of the major dial-backs under Trump that signaled the isolationism that so far has hurt the dollar. However, generally, bonds, at least in the US market, are seeing yields go down even though there are reinflationary signs from PPI —there could be a flight to bond markets in Europe and maybe even Japan (though less likely due to the other concerns around J-bonds) to deal with the global risks to equities from higher oil prices sure to follow the closing of the Strait of Hormuz and the effective oil supply reduction that will result. Breakdown and Comps Geography (iShares) Focusing on geographies here, there is quite a lot of Japan, but ...
Just days after showing off the Galaxy S26 , Samsung is finally rolling out the ability for users to unlock their home with a tap of their phone or by simply approaching their door. The new feature, called Digital Home Key, will live inside Samsung Wallet and is powered by the Aliro smart home standard. Samsung first teased its Digital Home Key feature in 2024 and said the feature would be availab...
Just days after showing off the Galaxy S26 , Samsung is finally rolling out the ability for users to unlock their home with a tap of their phone or by simply approaching their door. The new feature, called Digital Home Key, will live inside Samsung Wallet and is powered by the Aliro smart home standard. Samsung first teased its Digital Home Key feature in 2024 and said the feature would be available in 2025. That didn't pan out, as the CSA's Aliro standard - which will let users unlock smart locks with any phone - only arrived in February of this year. The new standard uses near-field communication (NFC) for its tap-to-unlock technology. It … Read the full story at The Verge.
In this article NVO LLY NVO Follow your favorite stocks CREATE FREE ACCOUNT Novo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its production capacities to make the newly launched Wegovy pill, the Danish drugmaker said Monday. The news comes about two months after Novo launched its blockbuster weight loss drug Wegovy in pill form in the U.S. market, i...
In this article NVO LLY NVO Follow your favorite stocks CREATE FREE ACCOUNT Novo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its production capacities to make the newly launched Wegovy pill, the Danish drugmaker said Monday. The news comes about two months after Novo launched its blockbuster weight loss drug Wegovy in pill form in the U.S. market, in what has been described as one of the strongest launches ever. "With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities for oral products, which will strengthen our ability to meet both current and future demand, outside the US," said Kasper Bødker Mejlvang, Novo's executive vice president of chemistry, manufacturing and controls and product supply. It follows Novo Nordisk losing market share to Eli Lilly , and investors doubting that its pipeline holds enough promise to win it back. The stock has tumbled as a result, and currently trades at roughly a quarter of what it did at its peak in mid-2024. "The investment is a sign of increasing focus and bet on the oral space from Novo Nordisk – an area where Novo has an edge," Jyske Bank analyst Henrik Hallengreen Laustsen told CNBC Monday. Ensuring Wegovy supply Novo enjoyed a first-mover advantage in the anti-obesity market and launched its GLP-1 drug semaglutide, sold as Ozempic and Wegovy, years before Lilly's rival medicine. It did, however, misjudge the demand for its weight loss jabs. With semaglutide in short supply, compounding pharmacies were allowed to flourish through a loophole in U.S. regulations, which allows the legal making of patented drugs during a shortage. Supply issues have since been resolved as Novo ramped up manufacturing capacity. Even so, compunders continue to sell cheaper copycat versions of the drug, and it is still weighing on Novo's sales . The company is involved in multiple legal battles over intellectual property. Novo has repeatedly said it has enough ...